CABA
Cabaletta Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.43
−1.42%Aug 13, 2026, 00:00 UTC
Cabaletta Bio reported a net loss of $51.0 million for Q2 2026, with diluted EPS of -$0.34, and cash and investments of approximately $225.1 million as of June 30, 2026, expected to fund operations through mid-2027.